logo-loader
viewValiRx PLC

ValiRx PLC gets go-ahead to expand and accelerate early-stage cancer study

George Morris, chief operations officer at ValiRx Plc (LON:VAL) tells Proactive the've been given the go-ahead by regulators to expand and accelerate their early-stage cancer study.

The Medicines and Healthcare Regulator Agency and Research Ethics Committee are allowing them to substantially raise the dosing of VAL201, a treatment for metastatic prostate cancer and other solid tumours.

They'll be doing this to find the correct therapeutic levels of treatment to administer in order to try to stop the disease’s spread.

Quick facts: ValiRx PLC

Price: 7.75 GBX

AIM:VAL
Market: AIM
Market Cap: £1.39 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Commercial discussions for ValiRx's lead cancer drug progressing 'rapidly'

George Morris, chief operations officer of ValiRx Plc (LON:VAL), tells Proactive's Andrew Scott commercial discussions to take their lead drug VAL 401 into a Phase III trial are progressing rapidly. He says by nature they're detailed and complex but he hopes they'll be completed shortly...

on 6/9/18

2 min read